CVC Credit has provided financial support for the joint acquisition of Immedica Pharma by KKR and Impilo, aiming to enhance the capabilities of the Swedish pharmaceutical company specializing in rare and specialty diseases.

Target Information

CVC Credit, a prominent global credit management firm managing €41 billion in assets, has announced its provision of debt facilities to facilitate the joint acquisition of Immedica Pharma. Immedica, a leading pharmaceutical company based in Stockholm, Sweden, specializes in launching and commercializing treatments for rare and specialty diseases. Their focus areas include genetic and metabolic disorders, hematology, oncology, and specialty care, which positions them strategically within the pharmaceutical market.

The company boasts a comprehensive operational framework encompassing marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory affairs, medical affairs, and market access. With a robust global distribution network, Immedica serves patients in over 50 countries across Europe, the Middle East, and North Africa, demonstrating its extensive reach and commitment to addressing complex healthcare needs.

Industry Overview in Sweden

The pharmaceutical industry in Sweden is characterized by a strong emphasis on innovation and research and development. Sweden ranks highly in global healthcare metrics and has a well-established infrastructure for clinical resear